Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington’s Disease Patients

– FDA lifts PTC518 partial clinical hold based on PIVOT-HD data – – Conference call and webcast to be held June 20th at 8:00 am EDT – WARREN, N.J., June 20, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in…